EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers

Natalie Y L Ngoi iD, Tin-Yun Tang iD, Catia F Gaspar, Dean C Pavlick iD, Gregory M Buchold, Emma L Scholefield, Vamsi Parimi, Richard S P Huang, Tyler Janovitz, Natalie Danziger, Mia A Levy, Shubham Pant und 5 weitere

The Oncologist · 03.06.2024 · 29 (6) · 493-503

DOI: 10.1093/oncolo/oyae011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 08.02.2024. Verfasst von Natalie Y L Ngoi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Gastrointestinal Neoplasms, Purine-Nucleoside Phosphorylase. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

One of the most common sporadic homozygous deletions in cancers is 9p21 loss, which includes the genes methylthioadenosine phosphorylase (MTAP), CDKN2A, and CDKN2B, and has been correlated with worsened outcomes and immunotherapy resistance. MTAP-loss is a developing drug target through synthetic lethality with MAT2A and PMRT5 inhibitors. The purpose of this study is to investigate the prevalence and genomic landscape of MTAP-loss in advanced gastrointestinal (GI) tumors and investigate its role as a prognostic biomarker. Materials and Methods We performed next-generation sequencing and comparative genomic and clinical analysis on an extensive cohort of 64 860 tumors comprising 5 GI cancers. We compared the clinical outcomes of patients with GI cancer harboring MTAP-loss and MTAP-intact tumors in a retrospective study.

Results

The prevalence of MTAP-loss in GI cancers is 8.30%. MTAP-loss was most prevalent in pancreatic ductal adenocarcinoma (PDAC) at 21.7% and least in colorectal carcinoma (CRC) at 1.1%. MTAP-loss tumors were more prevalent in East Asian patients with PDAC (4.4% vs 3.2%, P = .005) or intrahepatic cholangiocarcinoma (IHCC; 6.4% vs 4.3%, P = .036). Significant differences in the prevalence of potentially targetable genomic alterations (ATM, BRAF, BRCA2, ERBB2, IDH1, PIK3CA, and PTEN) were observed in MTAP-loss tumors and varied according to tumor type. MTAP-loss PDAC, IHCC, and CRC had a lower prevalence of microsatellite instability or elevated tumor mutational burden. Positive PD-L1 tumor cell expression was less frequent among MTAP-loss versus MTAP-intact IHCC tumors (23.2% vs 31.2%, P = .017).

Conclusion

In GI cancers, MTAP-loss occurs as part of 9p21 loss and has an overall prevalence of 8%. MTAP-loss occurs in 22% of PDAC, 15% of IHCC, 8.7% of gastroesophageal adenocarcinoma, 2.4% of hepatocellular carcinoma, and 1.1% of CRC and is not mutually exclusive with other targetable mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal NeoplasmsPurine-Nucleoside PhosphorylaseAdultAgedFemaleHumansMaleMiddle AgedBiomarkers, TumorGenomicsPrognosisRetrospective Studies

Stichwörter der Autor:innen

9p21 lossMTAP lossbiomarkerscholangiocarcinomagenomicstumor

Substanzen

5'-methylthioadenosine phosphorylaseBiomarkers, TumorPurine-Nucleoside PhosphorylaseMTAP protein, human

Autor:innen und Institutionen

  • Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.
  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Foundation Medicine Inc., Cambridge, MA, USA.
  • Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde Glasgow, Glasgow, UK.
  • Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Natalie Y L Ngoi, Tin-Yun Tang, Dean C Pavlick, Anaemy Danner De Armas, Jeffrey S Ross, Milind Javle, Jordi Rodon Ahnert

Zitieren

APA

Ngoi, N. Y. L., Tang, T. Y., Gaspar, C. F., Pavlick, D. C., Buchold, G. M., Scholefield, E. L., Parimi, V., Huang, R. S. P., Janovitz, T., Danziger, N., Levy, M. A., Pant, S., De Armas, A. D., Kumpula, D., Ross, J. S., Javle, M., & Rodon Ahnert, J. (2024). Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers. The Oncologist, 29(6), 493-503. https://doi.org/10.1093/oncolo/oyae011

Vancouver

Ngoi NYL, Tang TY, Gaspar CF, Pavlick DC, Buchold GM, Scholefield EL, et al. Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers. The Oncologist. 2024;29(6):493-503. doi:10.1093/oncolo/oyae011

BibTeX
@article{Ngoi2024,
  author = {Ngoi, Natalie Y L and Tang, Tin-Yun and Gaspar, Catia F and Pavlick, Dean C and Buchold, Gregory M and Scholefield, Emma L and Parimi, Vamsi and Huang, Richard S P and Janovitz, Tyler and Danziger, Natalie and Levy, Mia A and Pant, Shubham and De Armas, Anaemy Danner and Kumpula, David and Ross, Jeffrey S and Javle, Milind and Rodon Ahnert, Jordi},
  title = {Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {6},
  pages = {493--503},
  doi = {10.1093/oncolo/oyae011}
}
Kostenlos starten →